xing Fu Li

xing Fu Li


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2023 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
ZSZhiyong Sheng
Zhiyong Sheng
ZYZhihong Yu
Zhihong Yu
MWMeng Wang
Meng Wang
RZRui Zhou
Rui Zhou
SCShenjian Chen
Shenjian Chen
XLxing Fu Li
xing Fu Li
Sepsis-induced muscle weakness is a debilitating consequence of prolonged critical illness, often associated with a poor prognosis. While recent research has shown that STAT6 functions as an inhibitor of myogenesis, its role in sepsis-induced muscle weakness remains unclear. In this study, we hypothesized that inhibiting STAT6 could attenuate sepsis-induced muscle atrophy and weakness, and we explored the underlying mechanisms. Leveraging a microarray dataset from sepsis patients, we identified significant enrichment of genes related to muscle function, ferroptosis, and the p53 signalling pathway in muscle tissue from sepsis patients. Using a murine sepsis model induced by cecum ligation and puncture (CLP), we explore the multifaceted role of STAT6 inhibition. Our findings demonstrate that STAT6 inhibition effectively attenuates muscle atrophy, enhances grip strength, preserves mitochondrial integrity, and modulates ferroptosis in septic mice. Additionally, we identify elevated levels of CHI3L1 in septic muscle tissue, which are significantly reduced by STAT6 inhibition. In-depth analysis of primary muscle satellite cells reveals that CHI3L1 overexpression is associated with increased expression of key regulators of satellite cell myogenicity, while negatively impacting cell viability. Silencing CHI3L1 expression mitigates satellite cell injury and loss, highlighting its pivotal role in sepsis-induced muscle damage. In summary, this study unveils the potential of STAT6 as a therapeutic target for mitigating sepsis-induced muscle atrophy and weakness. Our findings underscore the regulation of mitochondrial dysfunction, ferroptosis, and CHI3L1-mediated satellite cell damage by STAT6, offering promising avenues for therapeutic intervention in the management of sepsis-induced muscle weakness.

19 November 2025 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
YYYing Yuan
Ying Yuan
GFGanyue Fu
Ganyue Fu
YZYunqiang Zhu
Yunqiang Zhu
JXJianning Xu
Jianning Xu
XLxing Fu Li
xing Fu Li
ZSZhiyong Sheng
Zhiyong Sheng

17 December 2025 in Research Square
Verified
Preprint
Open access
PDF file
EWEn Wei
En Wei
XLxing Fu Li
xing Fu Li
FZFei Zhao
Fei Zhao
Objective To assess the association between the lactate to hematocrit ratio (LHR) at ICU admission and all cause mortality at 28-day and 360-day in patients with acute myocardial infarction (AMI) and to test its added value beyond established severity scores. Methods This retrospective study used data from the Medical Information Mart for Intensive Care IV database (MIMIC IV, version 3. 1). Adult ICU patients with AMI were included. We applied multivariable Cox regression, receiver operating characteristic (ROC) analysis, Kaplan-Meier curves, subgroup analyses, and sensitivity analyses to examine the relation between admission LHR and 28-day and 360-day mortality. Results A total of 2884 patients were included. Compared with Q1, patients in Q4 had higher mortality risk at 28-days (hazard ratio [HR] 1. 799, 95% confidence interval [CI] 1. 304 to 2. 481, P < 0. 001) and at 360-days (HR 1. 520, 95% CI 1. 152 to 2. 006, P = 0. 003). The area under the ROC curve (AUC) for LHR was 0. 802 for 28-day mortality and 0. 796 for 360-day mortality. Adding LHR to existing scores improved model discrimination and reclassification as shown by the integrated discrimination improvement (IDI) and the net reclassification improvement (NRI). Restricted cubic spline (RCS) analysis showed an almost linear dose response relation between LHR and mortality. Findings were consistent in the complete case analysis. Conclusion LHR is an independent risk factor for short term and long term mortality in ICU patients with AMI. Adding LHR to current models improves prediction and may help identify high risk patients. Trial registration: Not applicable.